Patents or Trade Secrets? When to Patent in Deep Tech Innovation

​
May 11, 2026

Why IP Strategy Matters for Deep Tech Companies

Protecting your business and products from being copied or otherwise exploited is always important, particularly for companies developing deep tech technologies. Advanced hardware, electronics, and the processes used to design, manufacture, or operate them, require a particular approach. Long development cycles and high upfront investment often delay commercial returns, making it essential to adopt an IP strategy that reflects how value is created, where technical advantage truly lies, and how competitors could realistically gain access to it.

Properly protected IP is widely recognised as a way of enhancing company value. This can be achieved by preventing others from using your technology without permission, but equally by creating defensible barriers that deter entry or imitation. A recurring strategic question for deep tech companies is whether protection should take the form of patents, trade secrets, or, more often, a carefully structured combination of the two.

Reverse Engineering and the Risk of Imitation

For a competitor to copy a technology, the relevant technical details must be known or discoverable. Physical hardware, such as circuit designs, can sometimes be reverse-engineered, although complex systems may require sophisticated techniques, including X‑ray imaging, electron microscopy, or focused ion beam analysis. While these approaches can be costly and time‑consuming, they may still be commercially viable where the upside is large enough.

Importantly, competitive advantage in deep tech does not arise solely from products. Many businesses also rely heavily on processes: manufacturing methods, calibration routines, materials processing steps, test methodologies, control algorithms, or system‑level integration techniques. These processes often deliver critical improvements in performance, yield, reliability, or cost, yet may not be directly observable from the final product.

Detectability and Enforceability in Practice

In some business models, disclosure is unavoidable. Semiconductor IP, for example, may be licensed in the form of RTL code such as Verilog or VHDL, making the underlying design visible to customers and their engineers. In these scenarios, trade secrets alone can be fragile. Patent protection may provide clearer and more enforceable rights, particularly where multiple organisations need access to the same core technology.

Detectability plays a central role in the patent versus trade secret decision. If a competitor cannot readily determine how a technology works, it may also be difficult for the rights holder to detect or prove infringement. Patents are often best suited to technologies that are likely to be discovered through product inspection, disclosed to third parties, or independently developed. They provide a defined scope of protection and a structured enforcement framework. When drafted with detectability in mind, patents can be aligned with externally observable behaviour or measurable system outputs, improving their practical enforceability even for complex technologies.

Using Trade Secrets to Protect Internal Know‑How

Trade secrets, by contrast, are often well suited to internally used processes and know‑how that never need to be disclosed outside the organisation. This includes manufacturing techniques, tuning parameters, workflow optimisations, and other operational knowledge. Effective trade secret protection depends on technical, contractual, and organisational controls, including restricted access, confidentiality obligations, and careful documentation. In the EU, this requires compliance with the Trade Secrets Directive (EU Directive 2016/94).

Employee mobility presents additional challenges. Process‑based know‑how is often harder to protect once key personnel move to competitors, particularly where similar results can be achieved through parallel development. In such cases, patents covering core technical concepts, even where specific implementation details remain confidential, can provide a valuable backstop.

Combining Patents and Trade Secrets for Stronger Protection

In practice, the strongest deep tech IP strategies deliberately combine patents and trade secrets. Patents can secure protection for externally visible innovations and strategically important technical ideas, while trade secrets safeguard sensitive processes and execution know‑how that deliver practical advantage. Determining the right balance is highly technology‑specific and closely tied to commercial objectives.

‍

Early advice from experienced patent attorneys is therefore critical. At EIP, we work with companies developing complex deep tech systems to build IP strategies that align legal protection with technical reality and business goals. Through our Ampliphy offering, clients gain access to patent attorneys specialising in electronics, semiconductors, and advanced processes, ensuring informed decisions at the intersection of innovation, IP, and commercial strategy. To explore how a combined patent and trade secret strategy could work for your technology, contact Andrew Thompson or Filip Jörgensen for a discussion.

‍

‍

The Latest Thought Leadership pieces in the Content Hub

No items found.
Stay in the Know

The Patent Strategist

Get expert insights and the top patent stories delivered straight to your inbox.

Heading
This is some text inside of a div block.
This is some text inside of a div block.

Latest Insights

Showing 0 of 100
The UPC After Three Years: From Experiment to Enforcement Forum
15 July 2026
1,282 cases filed at the UPC in three years: infringement actions have surged while revocation filings stayed flat, easing fears the Court would become a European patent graveyard.
Choosing your SEP battleground: UPC, Germany or UK?
07 June 2026
Choosing the right venue for SEP litigation can significantly influence the outcome of FRAND disputes. This article compares the UPC, German and UK courts, examining their approaches to injunctions, FRAND defences, rate-setting and enforcement. It highlights the strategic advantages of each jurisdiction and explains why many SEP owners are increasingly turning to the UK and UPC as part of their European enforcement strategy.
Synthetic Lethality & AI: IP Strategy in Oncology
26 May 2026
This article explores the resurgence of synthetic lethality in precision oncology, highlighting how AI and machine learning are accelerating the discovery of new therapeutic targets. It also examines growing clinical activity, investment, and the evolving intellectual property challenges shaping this emerging field.
Inside the Visser AI Launch Party
20 May 2026
EIP has officially launched Visser AI®, our hybrid intelligence service for patent drafting and prosecution. Watch the launch film from our event at The Boundary in Shoreditch, and discover how our team of European and US patent attorneys — working with the Patently AI platform , delivers faster, lower-cost work at the EPO, USPTO and beyond.
Protecting Your Startup: Five Intellectual Property Mistakes to Avoid
20 May 2026
Early‑stage startups often focus on product development and fundraising, but overlooking intellectual property (IP) can seriously damage long‑term value. This article explores five common IP mistakes startups make, with a particular focus on patents. It covers the risks of filing patents without professional advice, making public disclosures too early, failing to put enforceable contracts in place with third parties, misunderstanding what patent rights actually provide, and neglecting to develop a clear IP strategy. By highlighting these pitfalls and offering practical guidance, the article helps startups protect their innovations, strengthen their commercial position, and improve their prospects with investors.
Technology, Patents, and Sport
13 May 2026
VAR, goal-line tech, AI 3D player avatars, wearable trackers, the technology reshaping the 2026 World Cup and elite sport rests on a patent system that makes the R&D investment behind it worth taking.
Patents or Trade Secrets? When to Patent in Deep Tech Innovation
11 May 2026
Deep tech companies face unique IP challenges due to long development cycles, high upfront investment, and complex technologies that combine products and processes. This article explores when patents, trade secrets, or a combination of both offer the strongest protection. It explains how factors such as detectability, reverse engineering risk, disclosure to third parties, and employee mobility should shape IP strategy decisions. While patents are often best suited to externally visible or licensable technologies, trade secrets can be highly effective for internal processes and know‑how that deliver performance or cost advantages.
Is Your AI Conversation Privileged?
08 May 2026
Recent US court decisions have, for the first time, tested whether conversations with AI tools can be protected by legal privilege. In United States v. Heppner, a court held that documents generated by a defendant using a public AI platform were not protected by attorney‑client privilege, largely because the AI was not used within a lawyer‑directed relationship and the platform’s terms allowed data retention and disclosure. By contrast, in Warner v. Gilbarco, another court found that AI‑assisted materials created by a self‑represented litigant were protected under the work‑product doctrine, which has a more forgiving standard for waiver.
The evolution of nucleic acid sequencing and what it means for Genomics and IP
27 April 2026
This article outlines the evolution of nucleic acid sequencing, from early Sanger methods to next‑generation and long‑read technologies. The journey from deciphering individual DNA strands to sequencing entire genomes in hours represents one of biotechnology's most impressive transformations. The first human genome, completed through the Human Genome Project, took around 13 years to sequence and cost billions of dollars, whereas modern sequencing methods can now deliver a genome in hours for a few hundred dollars. For those interested in patents and life sciences, understanding the technical evolution of sequencing methods offers insights into how fundamental scientific advances translate into valuable patent portfolios.
World IP Day: The big ideas shaping IP's fastest-moving fields
24 April 2026
For World IP Day, we asked experts of EIP’s five growth areas: Uniphy, Ampliphy, Stratiphy, Codiphy and Quantiphy, to share a quick insight on innovation, IP trends, and what excites them about the future. Each responded to a single, focused question reflecting the role their team plays across EIP.
Meet the EIP team heading to INTA 2026 in London
23 April 2026
INTA's Annual Meeting is coming to London. From 2–6 May 2026, the ExCeL will host more than 10,000 trade mark and IP professionals from over 100 jurisdictions — five days of sessions, side events, and the kind of corridor conversations that turn into lasting working relationships.
National offices report increases in national patent applications throughout Europe: Is the EPO no longer “killing” the national offices?
27 March 2026
National patent offices across Europe have reported a marked increase in patent filings in 2025, breaking with a long‑standing downward trend. Data from Germany, France, Italy, Sweden, Austria, Spain and Norway point to growing activity driven by digital technologies, electrification and increased university participation. At the same time, offices report a rise in self‑drafted and AI‑assisted applications, which may lower barriers to entry but also raise concerns about application quality and examination efficiency.
Make your bio(pharma) IP investment ready
22 March 2026
This recap of our LinkedIn Live series focuses on helping (bio)pharma businesses make their IP investment‑ready. Across three sessions, experts will discuss building resilient IP portfolios, making strategic IP decisions ahead of funding rounds, and what the evolving 2026 (bio)pharma landscape means for long‑term IP strategy.
Are professional guidelines making Patent Attorneys too cautious on AI?
19 February 2026
As AI use accelerates in patent practice, many European patent attorneys remain cautious due to professional AI guidelines from the epi. This article argues those guidelines are not a barrier, but a baseline for responsible use.
Beyond CRISPR: Precision to Platform
23 January 2026
Gene editing is entering a new phase, moving beyond CRISPR-Cas9’s breakthrough but costly, bespoke therapies toward more precise and scalable platforms. While CRISPR-based treatments like Casgevy have proven clinical success, they remain expensive and entangled in ongoing patent disputes over foundational IP. Next-generation tools such as base editing and prime editing avoid double-strand DNA breaks, enabling more accurate corrections and broader therapeutic potential. The field’s focus is now shifting to disease-agnostic platforms that can be adapted across many conditions, improving access and efficiency.